Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Addex Therapeutics Ltd (ADXN)

1.06   0.02 (1.92%) 01-27 16:00
Open: 1.08 Pre. Close: 1.04
High: 1.11 Low: 1.03
Volume: 305,051 Market Cap: 20(M)

Technical analysis

as of: 2023-01-27 4:42:18 PM
Overall:       
Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 1.29     One year: 1.51
Support: Support1: 0.76    Support2: 0.55
Resistance: Resistance1: 1.11    Resistance2: 1.29
Pivot: 0.87
Moving Average: MA(5): 1     MA(20): 0.82
MA(100): 0.78     MA(250): 2.33
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 91.7     %D(3): 94.2
RSI: RSI(14): 77
52-week: High: 6.23  Low: 0.55
Average Vol(K): 3-Month: 185 (K)  10-Days: 228 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ ADXN ] has closed below upper band by 6.1%. Bollinger Bands are 90.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.11 - 1.12 1.12 - 1.12
Low: 1.02 - 1.02 1.02 - 1.03
Close: 1.05 - 1.06 1.06 - 1.07

Company Description

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot–Marie–Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.

Headline News

Fri, 27 Jan 2023
Addex Therapeutics Ltd - ADR (ADXN) has risen 7.69% Friday In Premarket Trading - InvestorsObserver

Wed, 18 Jan 2023
Addex Provides Corporate Update and Financial Guidance - Yahoo Finance

Wed, 07 Dec 2022
Addex and Indivior Extend Research Term of Substance Use Disorder GABAB Positive Allosteric Modulator Discovery Collaboration - Yahoo Finance

Thu, 10 Nov 2022
Addex Reports Q3 2022 Financial Results and Provides Corporate Update - Yahoo Finance

Wed, 02 Nov 2022
Addex Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference Call on November 11, 2022 - Yahoo Finance

Tue, 01 Nov 2022
Addex Increases Issued Share Capital to Create Treasury Shares - GlobeNewswire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 19 (M)
% Held by Insiders 4.02e+006 (%)
% Held by Institutions 0 (%)
Shares Short 110 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -2.151e+007
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -1
Return on Assets (ttm) 707.4
Return on Equity (ttm) -87.9
Qtrly Rev. Growth 1.25e+006
Gross Profit (p.s.) -27.67
Sales Per Share -124.34
EBITDA (p.s.) -5.94479e+006
Qtrly Earnings Growth -3.3
Operating Cash Flow 0 (M)
Levered Free Cash Flow -16 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.01
Price to Cash Flow 1.91

Stock Dividends

Dividend 0
Forward Dividend 34860
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.